Trust Size
$14M
Peak Price
$1654.80
Current Price
$0.29
Return
-97.1%
Price Journey
What Happened
Calidi Biotherapeutics is a clinical-stage biotechnology company developing oncolytic virus-based immunotherapies for cancer treatment, delivered through proprietary stem cell platforms.
Calidi Biotherapeutics went public through a SPAC merger and uses stem cells as delivery vehicles for cancer-killing viruses directly to tumors. The approach aims to overcome the immune system's tendency to neutralize viruses before they reach cancer cells. The stock has declined dramatically, with the company facing the cash-intensive challenges typical of early-stage oncology biotechs.
Timeline
2021-09-07
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1855485
Total SEC Filings
374
State of Incorporation
DE
Last Filing Date
2026-03-11
Business Location
Reston, VA
Trust/Asset Size
$14M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Calidi Biotherapeutics